Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, filed on Tuesday with the SEC to raise up to $60 million in an initial public offering. The Dublin, Ireland-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol NVET. Nexvet initially filed confidentially on September 5, 2014. BofA Merrill Lynch and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
